<DOC>
	<DOCNO>NCT02801903</DOCNO>
	<brief_summary>This 21 day , single-center , open-label pharmacokinetic , safety tolerability study adolescent moderate severe acne vulgaris .</brief_summary>
	<brief_title>Pharmacokinetics Topical SB204 Adolescents With Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Otherwise healthy male female adolescent subject moderate severe acne vulgaris 5 point IGA scale At least 20 total inflammatory lesion ( papule pustule ) , least 20 total noninflammatory lesion ( open close comedo ) face , chest , back , shoulder Age 916 year , 11 month inclusive Subjects methemoglobin level le 3 % Screening Baseline pulse cooximeter Subjects acnelike dermatological condition severe , recalcitrant nodulocystic acne , acne conglobata , acne fulminans , acne secondary medication medical condition , perioral dermatitis , clinically significant rosacea , gramnegative folliculitis ; Any subject skin disorder acute chronic nature include psoriasis , eczema , tinea versicolor , etc . Subjects reside dwell relies well water primary drinking source Subjects facial hair ( beard , mustache , etc . ) , tattoos facial marking would interfere assessment study drug application Transgender subject receive hormone supplement ( male female female male ) Subjects previous history methemoglobinemia take medication know associated methemoglobinemia Subjects know history HIV , hepatitis , bloodborne pathogen Females pregnant , plan pregnancy breastfeed Subjects previously treat NVN1000 Gel / SB204</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>